Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.08
GNBT's Cash-to-Debt is ranked lower than
96% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. GNBT: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
GNBT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 5.65 Max: No Debt
Current: 0.08
0
No Debt
Equity-to-Asset -0.94
GNBT's Equity-to-Asset is ranked lower than
100% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GNBT: -0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
GNBT' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.41  Med: 0.41 Max: 0.94
Current: -0.94
-6.41
0.94
Debt-to-Equity -1.48
GNBT's Debt-to-Equity is ranked lower than
99.99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. GNBT: -1.48 )
Ranked among companies with meaningful Debt-to-Equity only.
GNBT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.48  Med: 0.08 Max: 27.04
Current: -1.48
-1.48
27.04
Debt-to-EBITDA 1.11
GNBT's Debt-to-EBITDA is ranked higher than
57% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. GNBT: 1.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GNBT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.18  Med: -0.11 Max: 1.11
Current: 1.11
-0.18
1.11
Piotroski F-Score: 5
Altman Z-Score: -22.16
Beneish M-Score: 1077.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -143.10
GNBT's Operating Margin % is ranked lower than
64% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. GNBT: -143.10 )
Ranked among companies with meaningful Operating Margin % only.
GNBT' s Operating Margin % Range Over the Past 10 Years
Min: -34565.52  Med: -2508.95 Max: -143.1
Current: -143.1
-34565.52
-143.1
Net Margin % 1097.73
GNBT's Net Margin % is ranked higher than
99% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. GNBT: 1097.73 )
Ranked among companies with meaningful Net Margin % only.
GNBT' s Net Margin % Range Over the Past 10 Years
Min: -32724.14  Med: -4094.01 Max: 5168.42
Current: 1097.73
-32724.14
5168.42
ROA % 250.02
GNBT's ROA % is ranked higher than
99% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. GNBT: 250.02 )
Ranked among companies with meaningful ROA % only.
GNBT' s ROA % Range Over the Past 10 Years
Min: -1383.58  Med: -116.25 Max: 435.09
Current: 250.02
-1383.58
435.09
ROC (Joel Greenblatt) % 17105.87
GNBT's ROC (Joel Greenblatt) % is ranked higher than
100% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. GNBT: 17105.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNBT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7608900  Med: -1954.58 Max: 221406.06
Current: 17105.87
-7608900
221406.06
GuruFocus has detected 3 Warning Signs with Generex Biotechnology Corp GNBT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNBT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GNBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XSAT:ALTE, OTCPK:TIKRF, NZSE:PIL, LSE:AOR, ASX:ACL, TSXV:PBS, XSAT:INIT, XCNQ:PREV, XSAT:SLOTT B, OTCPK:CAPS, WAR:BLR, XSAT:PANION, OSTO:ANNX, TSXV:MFS, XSAT:PMED, OTCPK:STLT, OTCPK:MTST, OTCPK:NULF, OTCPK:SGBI, TSXV:IOT » details
Traded in other countries:GB8A.Germany,
Headquarter Location:USA
Generex Biotechnology Corp is engaged in the research and development of drug delivery systems and technologies for metabolic and immunological diseases.

Generex Biotechnology Corp is a US-based Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Ratios

vs
industry
vs
history
PE Ratio 4.55
GNBT's PE Ratio is ranked lower than
99.99% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. GNBT: 4.55 )
Ranked among companies with meaningful PE Ratio only.
GNBT' s PE Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.94 Max: 8.54
Current: 4.55
0.18
8.54
PE Ratio without NRI 4.55
GNBT's PE Ratio without NRI is ranked lower than
99.99% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. GNBT: 4.55 )
Ranked among companies with meaningful PE Ratio without NRI only.
GNBT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.18  Med: 1.94 Max: 8.54
Current: 4.55
0.18
8.54
Price-to-Owner-Earnings 2.87
GNBT's Price-to-Owner-Earnings is ranked higher than
99% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. GNBT: 2.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GNBT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.13  Med: 0.8 Max: 5.37
Current: 2.87
0.13
5.37
PS Ratio 24.19
GNBT's PS Ratio is ranked higher than
80% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNBT: 24.19 )
Ranked among companies with meaningful PS Ratio only.
GNBT' s PS Ratio Range Over the Past 10 Years
Min: 2.74  Med: 260 Max: 2489.09
Current: 24.19
2.74
2489.09
EV-to-EBIT 4.17
GNBT's EV-to-EBIT is ranked higher than
87% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. GNBT: 4.17 )
Ranked among companies with meaningful EV-to-EBIT only.
GNBT' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.2  Med: -1.7 Max: 6.5
Current: 4.17
-5.2
6.5
EV-to-EBITDA 4.16
GNBT's EV-to-EBITDA is ranked higher than
88% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. GNBT: 4.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.3  Med: -1.9 Max: 6.5
Current: 4.16
-6.3
6.5
EV-to-Revenue 46.28
GNBT's EV-to-Revenue is ranked higher than
51% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. GNBT: 46.28 )
Ranked among companies with meaningful EV-to-Revenue only.
GNBT' s EV-to-Revenue Range Over the Past 10 Years
Min: 10.8  Med: 525.6 Max: 5327.3
Current: 46.28
10.8
5327.3
Current Ratio 0.15
GNBT's Current Ratio is ranked lower than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. GNBT: 0.15 )
Ranked among companies with meaningful Current Ratio only.
GNBT' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.54 Max: 36.05
Current: 0.15
0.01
36.05
Quick Ratio 0.13
GNBT's Quick Ratio is ranked lower than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. GNBT: 0.13 )
Ranked among companies with meaningful Quick Ratio only.
GNBT' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.53 Max: 36.05
Current: 0.13
0.01
36.05
Days Inventory 74.34
GNBT's Days Inventory is ranked lower than
99.99% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. GNBT: 74.34 )
Ranked among companies with meaningful Days Inventory only.
GNBT' s Days Inventory Range Over the Past 10 Years
Min: 74.34  Med: 2010.64 Max: 11895.68
Current: 74.34
74.34
11895.68
Days Sales Outstanding 449.76
GNBT's Days Sales Outstanding is ranked lower than
99.99% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. GNBT: 449.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNBT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.25  Med: 18.29 Max: 449.76
Current: 449.76
11.25
449.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
GNBT's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. GNBT: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNBT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.2  Med: -24.8 Max: -9
Current: -9
-70.2
-9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.09
GNBT's Price-to-Median-PS-Value is ranked higher than
100% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. GNBT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNBT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.62 Max: 9.44
Current: 0.09
0.01
9.44
Earnings Yield (Greenblatt) % 23.97
GNBT's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. GNBT: 23.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNBT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -445.9  Med: -46 Max: 293.4
Current: 23.97
-445.9
293.4

More Statistics

Revenue (TTM) (Mil) $2.42
EPS (TTM) $ 0.33
Beta-4.29
Volatility348.48%
52-Week Range $0.08 - 3.10
Shares Outstanding (Mil)60.29

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}